Nuvectis Pharma gets FDA Orphan Drug Designation for NXP800 in ARID1a-deficient ovarian cancers

Nuvectis Pharma, Inc.

FDA granted Orphan Drug Designation for NXP800 for treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.
CEO Ron Bentsur noted prevalence exceeds 200,000 threshold; designation for a disease subset is uncommon.
Ongoing Phase 1b trial in platinum-resistant ARID1a-mutated ovarian cancer; data update expected fall 2024.
Nuvectis Pharma (NVCT) stock trades on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.